Somatic Cell Therapy

Somatic Cell Therapy encompasses therapeutic approaches using living autologous, allogeneic, or xenogeneic cells that have been manipulated or processed ex vivo before administration to patients, treating diseases through cellular mechanisms including replacement of damaged tissues, immune modulation, or targeted cell killing. Product categories include haematopoietic stem cell transplantation, mesenchymal stromal cells, CAR-T cells, tumour-infiltrating lymphocytes, and numerous investigational cellular products.

The biopharmaceutical industry has transformed cell therapy from experimental approaches to approved products treating cancers, genetic disorders, and degenerative diseases. Manufacturing presents unique challenges including patient-specific processing for autologous products, maintaining cell viability and function, ensuring sterility without terminal sterilisation, and complex supply chains coordinating collection, processing, and delivery. Quality control employs identity testing confirming correct patient material, potency assays measuring therapeutic function, purity assessments quantifying desired cells, and extensive characterisation ensuring consistency. Regulatory frameworks address complexity through comprehensive Chemistry, Manufacturing, and Controls sections with long-term follow-up monitoring. Cryopreservation enables decoupling manufacturing from administration. Scalability challenges drive development of allogeneic off-the-shelf alternatives. As manufacturing technologies advance through automation and process optimisation, somatic cell therapy applications expand offering transformative treatments through living cellular medicines.